摘要
[目的]探讨盐酸埃克替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。[方法]对2011年9月至2012年9月间收治的42例晚期NSCLC患者进行随访观察,治疗方案为口服盐酸埃克替尼,125mg/次,3次/d,评价其近期和远期疗效以及不良反应。[结果]全组42例患者用药1个周期后,部分缓解11例,疾病稳定22例,疾病进展9例,客观有效率26.2%,疾病控制率78.6%。不良反应总发生率为52.4%,主要为皮疹(23.8%)、皮肤瘙痒(14.3%)及腹泻(9.5%)。近期疗效与患者性别、病理类型相关(P<0.05)。PFS与患者性别、病理类型、ECOG评分相关,差异有统计学意义(P<0.05)。[结论]盐酸埃克替尼治疗晚期NSCLC疗效肯定,且毒性低、安全性高、耐受性好,为晚期NSCLC患者的新选择。
[Purpose] To evaluate the efficacy and toxicities of icotinib in 42 patients with advanced NSCLC. [Methods] Forty-two patients with advanced NSCLC were enrolled from September 2011 to September 2012. Patients were treated with icotinib （125mg,three times a day）. The short-term re- sponse ,long-term response,toxicity and quality of life were evaluated. [Results] Among the 42 pa- tients, 11 cases were partial response（PR）; 22 cases,stable disease（SD） and 9 cases,progression dis- ease（PD）.The objective response rate（ORR） was 26.2% and disease control rate（DCR） was 78.6%. The overall incidence rate of toxicity was 52.4%,including rash（23.8%）, dry skin（14.3%）,and diarrhea （9.5%）. Short-term response correlated with pathological type and gender （P〈O.05）. Long-term response cor- related with pathological type,gender and ECOG scores （P〈0.05）. [Conclusion] Ieotinib is effective in the treatment for advanced NSCLC,with low toxicity, good safety and tolerability.
出处
《中国肿瘤》
CAS
2013年第6期497-501,共5页
China Cancer
